Imatinib mesylate induces durable complete remission of advanced CML persisting after allogeneic bone marrow transplantation. [electronic resource]
Producer: 20030411Description: 458-60 p. digitalISSN:- 0887-6924
- Antineoplastic Agents -- therapeutic use
- Benzamides
- Bone Marrow Cells -- pathology
- Bone Marrow Transplantation
- Follow-Up Studies
- Humans
- Imatinib Mesylate
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive -- drug therapy
- Leukocyte Count
- Piperazines -- therapeutic use
- Pyrimidines -- therapeutic use
- Remission Induction
- Transplantation, Homologous
No physical items for this record
Publication Type: Clinical Trial; Letter; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.